| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 905.05K | 5.63M |
| Revenue Growth % | - | - | - | 5.22% |
| Cost of Goods Sold | 0 | 0 | 1.05M | 5.15M |
| COGS % of Revenue | - | - | 1.16% | 0.92% |
| Gross Profit | 0 | 0 | -143.31K | 472.58K |
| Gross Margin % | - | - | -0.16% | 0.08% |
| Gross Profit Growth % | - | - | - | 4.3% |
| Operating Expenses | 13.8K | 3.65M | 6.51M | 9.52M |
| OpEx % of Revenue | - | - | 7.19% | 1.69% |
| Selling, General & Admin | 13.8K | 2.63M | 47.67M | 7.18M |
| SG&A % of Revenue | - | - | 52.67% | 1.28% |
| Research & Development | 0 | 985.16K | 1.35M | 1.77M |
| R&D % of Revenue | - | - | 1.49% | 0.32% |
| Other Operating Expenses | 0 | 38.98K | -42.51M | 564.22K |
| Operating Income | -13.8K | -1.72M | -6.65M | -9.04M |
| Operating Margin % | - | - | -7.35% | -1.61% |
| Operating Income Growth % | - | -123.4% | -2.88% | -0.36% |
| EBITDA | 192.5K | -1.71M | -6.53M | -8.03M |
| EBITDA Margin % | - | - | -7.22% | -1.43% |
| EBITDA Growth % | - | -9.91% | -2.81% | -0.23% |
| D&A (Non-Cash Add-back) | 206.3K | 1.7K | 122.02K | 1.01M |
| EBIT | -13.8K | -3.65M | -51.86M | -7.19M |
| Net Interest Income | 0 | 11.19K | 532.99K | 773.43K |
| Interest Income | 0 | 13.32K | 693.03K | 1.94M |
| Interest Expense | 0 | 2.13K | 160.03K | 1.17M |
| Other Income/Expense | 0 | 1.62M | -45.37M | 703.55K |
| Pretax Income | -13.8K | -93.81K | -52.02M | -8.34M |
| Pretax Margin % | - | - | -57.48% | -1.48% |
| Income Tax | 0 | 0 | -234.54K | -1.05M |
| Effective Tax Rate % | 1% | 48.26% | 1% | 0.88% |
| Net Income | -13.8K | -4.53M | -51.79M | -7.31M |
| Net Margin % | - | - | -57.22% | -1.3% |
| Net Income Growth % | - | -326.99% | -10.44% | 0.86% |
| Net Income (Continuing) | -13.8K | -93.81K | -51.79M | -7.29M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.00 | -0.12 | -1.50 | -0.19 |
| EPS Growth % | - | - | -11.5% | 0.87% |
| EPS (Basic) | -0.00 | -0.12 | -1.50 | -0.19 |
| Diluted Shares Outstanding | 17.37M | 37.56M | 34.47M | 38.49M |
| Basic Shares Outstanding | 17.37M | 37.56M | 34.47M | 38.49M |
| Dividend Payout Ratio | - | - | - | - |
| Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | |
|---|---|---|---|---|
| Total Current Assets | 581.7K | 1.08M | 5.33M | 13.75M |
| Cash & Short-Term Investments | 337.6K | 1.08M | 2.83M | 5.39M |
| Cash Only | 337.6K | 1.08M | 2.53M | 5.39M |
| Short-Term Investments | 0 | 0 | 306.03K | 0 |
| Accounts Receivable | 0 | 0 | 1.69M | 1.48M |
| Days Sales Outstanding | - | - | 682.08 | 96.17 |
| Inventory | 0 | 0 | 465.75K | 6.28M |
| Days Inventory Outstanding | - | - | 162.16 | 444.83 |
| Other Current Assets | 244.09K | 0 | 0 | 0 |
| Total Non-Current Assets | 138.01M | 4.61M | 18.72M | 21.04M |
| Property, Plant & Equipment | 0 | 8.92K | 1.19M | 1.62M |
| Fixed Asset Turnover | - | - | 0.76x | 3.48x |
| Goodwill | 0 | 0 | 251.44K | 262.53K |
| Intangible Assets | 0 | 4.6M | 8.52M | 8.98M |
| Long-Term Investments | 138.01M | 138.01M | 8.76M | 10.15M |
| Other Non-Current Assets | 0 | -138.01M | 0 | 36.02K |
| Total Assets | 138.59M | 5.69M | 24.05M | 34.79M |
| Asset Turnover | - | - | 0.04x | 0.16x |
| Asset Growth % | - | -0.96% | 3.23% | 0.45% |
| Total Current Liabilities | 861.85K | 4.09M | 12.6M | 8.15M |
| Accounts Payable | 0 | 164.13K | 2.34M | 873.53K |
| Days Payables Outstanding | - | - | 814.39 | 61.88 |
| Short-Term Debt | 125K | 125K | 2.55M | 2.56M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 736.85K | 2.74M | 1.65M | 789.87K |
| Current Ratio | 0.67x | 0.27x | 0.42x | 1.69x |
| Quick Ratio | 0.67x | 0.27x | 0.39x | 0.92x |
| Cash Conversion Cycle | - | - | 29.85 | 479.12 |
| Total Non-Current Liabilities | 3.64M | 2.2M | 1.35M | 19.82M |
| Long-Term Debt | 0 | 0 | 99.05K | 11.7M |
| Capital Lease Obligations | 0 | 0 | 0 | 248.53K |
| Deferred Tax Liabilities | 0 | 0 | 1.07M | 72.1K |
| Other Non-Current Liabilities | 3.64M | 2.2M | 175.31K | 7.8M |
| Total Liabilities | 4.51M | 4.09M | 13.95M | 27.97M |
| Total Debt | 125K | 125K | 2.65M | 14.68M |
| Net Debt | -212.6K | -956.81K | 117.62K | 9.29M |
| Debt / Equity | 0.00x | 0.08x | 0.26x | 2.15x |
| Debt / EBITDA | 0.65x | - | - | - |
| Net Debt / EBITDA | -1.10x | - | - | - |
| Interest Coverage | - | -805.94x | -41.58x | -7.76x |
| Total Equity | 134.08M | 1.6M | 10.11M | 6.82M |
| Equity Growth % | - | -0.99% | 5.3% | -0.33% |
| Book Value per Share | 7.72 | 0.04 | 0.29 | 0.18 |
| Total Shareholders' Equity | 134.08M | 1.6M | 10.11M | 6.82M |
| Common Stock | 129.08M | 638.3K | 375.64K | 385.64K |
| Retained Earnings | -828.08K | -6.83M | -58.62M | -65.94M |
| Treasury Stock | - | 0 | 0 | -305K |
| Accumulated OCI | 0 | 0 | 18.11K | 125.71K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | |
|---|---|---|---|---|
| Cash from Operations | -8.8K | -915.08K | -7.51M | -9.33M |
| Operating CF Margin % | - | - | -8.3% | -1.66% |
| Operating CF Growth % | - | -102.96% | -7.21% | -0.24% |
| Net Income | -13.8K | -4.53M | -51.79M | -7.31M |
| Depreciation & Amortization | 0 | 1.7K | 122.02K | 1.01M |
| Stock-Based Compensation | 0 | 838.58K | 43.8M | 2.05M |
| Deferred Taxes | 0 | 860K | -234.54K | -1.05M |
| Other Non-Cash Items | 0 | 985.37K | -1.14M | -983.96K |
| Working Capital Changes | 5K | 926.18K | 1.73M | -3.05M |
| Change in Receivables | 0 | 0 | -44.13K | 273.09K |
| Change in Inventory | 0 | 0 | 66.48K | -5.79M |
| Change in Payables | 0 | 926.71K | 1.49M | 2.5M |
| Cash from Investing | 0 | -138M | -2.34M | 134.87K |
| Capital Expenditures | 0 | 0 | -179.19K | -158.28K |
| CapEx % of Revenue | - | - | 0.2% | 0.03% |
| Acquisitions | - | - | - | - |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 |
| Cash from Financing | 14.49K | 139.05M | 11.28M | 11.71M |
| Debt Issued (Net) | - | - | - | - |
| Equity Issued (Net) | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - |
| Other Financing | -306.71K | -403.89K | -24.1K | -1.38M |
| Net Change in Cash | - | - | - | - |
| Free Cash Flow | -8.8K | -1.89M | -7.69M | -9.49M |
| FCF Margin % | - | - | -8.5% | -1.69% |
| FCF Growth % | - | -213.27% | -3.08% | -0.23% |
| FCF per Share | -0.00 | -0.05 | -0.22 | -0.25 |
| FCF Conversion (FCF/Net Income) | 0.64x | 0.20x | 0.15x | 1.28x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
| Metric | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Return on Equity (ROE) | -0.01% | -6.67% | -884.5% | -86.42% |
| Return on Invested Capital (ROIC) | - | -1.91% | -91.81% | -51.52% |
| Gross Margin | - | - | -15.83% | 8.4% |
| Net Margin | - | - | -5722.22% | -129.99% |
| Debt / Equity | 0.00x | 0.08x | 0.26x | 2.15x |
| Interest Coverage | - | -805.94x | -41.58x | -7.76x |
| FCF Conversion | 0.64x | 0.20x | 0.15x | 1.28x |
| Revenue Growth | - | - | - | 521.53% |
Moolec Science S.A. (MLEC) reported $7.8M in revenue for fiscal year 2023.
Moolec Science S.A. (MLEC) grew revenue by 521.5% over the past year. This is strong growth.
Moolec Science S.A. (MLEC) reported a net loss of $8.3M for fiscal year 2023.
Moolec Science S.A. (MLEC) has a return on equity (ROE) of -86.4%. Negative ROE indicates the company is unprofitable.
Moolec Science S.A. (MLEC) had negative free cash flow of $6.1M in fiscal year 2023, likely due to heavy capital investments.